101 related articles for article (PubMed ID: 18279068)
1. mTOR pathway in renal cell carcinoma.
Hanna SC; Heathcote SA; Kim WY
Expert Rev Anticancer Ther; 2008 Feb; 8(2):283-92. PubMed ID: 18279068
[TBL] [Abstract][Full Text] [Related]
2. Molecular pathways in renal cell carcinoma--rationale for targeted treatment.
Kim WY; Kaelin WG
Semin Oncol; 2006 Oct; 33(5):588-95. PubMed ID: 17045088
[TBL] [Abstract][Full Text] [Related]
3. Prognostic role of histological necrosis for nonmetastatic clear cell renal cell carcinoma: correlation with pathological features and molecular markers.
Minervini A; Di Cristofano C; Gacci M; Serni S; Menicagli M; Lanciotti M; Salinitri G; Rocca CD; Lapini A; Nesi G; Bevilacqua G; Minervini R; Carini M
J Urol; 2008 Oct; 180(4):1284-9. PubMed ID: 18707725
[TBL] [Abstract][Full Text] [Related]
4. Clinical implications of hypoxia inducible factor in renal cell carcinoma.
Smaldone MC; Maranchie JK
Urol Oncol; 2009; 27(3):238-45. PubMed ID: 19414111
[TBL] [Abstract][Full Text] [Related]
5. Over expression of hypoxia-inducible protein 2, hypoxia-inducible factor-1alpha and nuclear factor kappaB is putatively involved in acquired renal cyst formation and subsequent tumor transformation in patients with end stage renal failure.
Konda R; Sugimura J; Sohma F; Katagiri T; Nakamura Y; Fujioka T
J Urol; 2008 Aug; 180(2):481-5. PubMed ID: 18550099
[TBL] [Abstract][Full Text] [Related]
6. Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia.
Chen J; Futami K; Petillo D; Peng J; Wang P; Knol J; Li Y; Khoo SK; Huang D; Qian CN; Zhao P; Dykema K; Zhang R; Cao B; Yang XJ; Furge K; Williams BO; Teh BT
PLoS One; 2008; 3(10):e3581. PubMed ID: 18974783
[TBL] [Abstract][Full Text] [Related]
7. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.
Malizzia LJ; Hsu A
Clin J Oncol Nurs; 2008 Aug; 12(4):639-46. PubMed ID: 18676330
[TBL] [Abstract][Full Text] [Related]
8. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma.
Kapoor A; Figlin RA
Cancer; 2009 Aug; 115(16):3618-30. PubMed ID: 19479976
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma.
Klatte T; Seligson DB; Riggs SB; Leppert JT; Berkman MK; Kleid MD; Yu H; Kabbinavar FF; Pantuck AJ; Belldegrun AS
Clin Cancer Res; 2007 Dec; 13(24):7388-93. PubMed ID: 18094421
[TBL] [Abstract][Full Text] [Related]
10. Opportunities and obstacles to combination targeted therapy in renal cell cancer.
Sosman JA; Puzanov I; Atkins MB
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):764s-769s. PubMed ID: 17255307
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
Figlin RA
Nat Clin Pract Oncol; 2008 Oct; 5(10):601-9. PubMed ID: 18607393
[TBL] [Abstract][Full Text] [Related]
12. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.
Hudes GR; Berkenblit A; Feingold J; Atkins MB; Rini BI; Dutcher J
Semin Oncol; 2009 Dec; 36 Suppl 3():S26-36. PubMed ID: 19963097
[TBL] [Abstract][Full Text] [Related]
13. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
[TBL] [Abstract][Full Text] [Related]
14. Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma.
Rini BI; Flaherty K
Urol Oncol; 2008; 26(5):543-9. PubMed ID: 18774471
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene.
Liu MY; Poellinger L; Walker CL
Cancer Res; 2003 May; 63(10):2675-80. PubMed ID: 12750296
[TBL] [Abstract][Full Text] [Related]
16. Targeting mTOR in renal cell carcinoma.
Hudes GR
Cancer; 2009 May; 115(10 Suppl):2313-20. PubMed ID: 19402072
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.
Motzer RJ; Bacik J; Schwartz LH; Reuter V; Russo P; Marion S; Mazumdar M
J Clin Oncol; 2004 Feb; 22(3):454-63. PubMed ID: 14752067
[TBL] [Abstract][Full Text] [Related]
18. Prognostic markers in renal cell carcinoma.
Ljungberg B
Curr Opin Urol; 2007 Sep; 17(5):303-8. PubMed ID: 17762621
[TBL] [Abstract][Full Text] [Related]
19. [Cytokine-based and targeted therapy of metastatic renal cell carcinoma--a current analysis].
Johannsen M; Ringsdorf M; Römer A; Loening SA; Roigas J
Aktuelle Urol; 2007 Jan; 38(1):38-45. PubMed ID: 17290328
[TBL] [Abstract][Full Text] [Related]
20. [Molecular characterization of metastatic renal cell carcinomas. Differentiation of prognosis and therapy].
Junker K; Sanjmyatav J; Heinze C; Walter M; Heinzelmann J; Wunderlich H; Schubert J; Steiner T
Urologe A; 2008 Sep; 47(9):1187-9. PubMed ID: 18688592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
